Inhalation of a dry powder tobramycin pulmosphere formulation in healthy volunteers

Chest

Volumn 124, Issue 1, 2003, Pages 360-366

  Newhouse, Michael T ^a   Hirst, Peter H ^b   Duddu, Sarma P ^a   Walter, Yulia H ^a   Tarara, Thomas E ^a   Clark, Andrew R ^a   Weers, Jeffry G ^a  

^a NEKTAR THERAPEUTICS   (United States)

^b PHARMACEUTICAL PROFILES LTD   (United Kingdom)

Author keywords

Anti infectives; Dry powder inhalation; Inhaled tobrarnycin; Nebulization; PulmoSphere; Turbospin

Indexed keywords

TECHNETIUM 99M; TOBRAMYCIN;

ADULT; AEROSOL; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TOLERABILITY; DRY POWDER; FEMALE; HUMAN; ISOTOPE LABELING; MALE; NEBULIZER; NORMAL HUMAN; POROSITY; POWDER INHALER; PRIORITY JOURNAL; REPRODUCIBILITY; SCINTIGRAPHY;

EID: 0038826781     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.124.1.360     Document Type: Article

References (16)

1. Goldman JM, Bayston SM, O'Connor S, et al. Inhaled micronized gentamycin powder: a new delivery system. Thorax 1990; 45:939-940
2. Crowther Labiris NR, Holbrook AM, Chrystyn H, et al. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. Am J Respir Crit Care Med 1999; 160:1711-1716
3. Weers J. Dispersible powders for inhalation applications. Innov Pharm Tech 2000; 1(7):111-116
4. Duddu S, Sisk SA, Walter YH, et al. Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere powder. Pharm Res 2002; 19:689-695
5. Dellamary LA, Tarara TE, Smith DJ, et al. Hollow porous particles in metered dose inhalers. Pharm Res 2000; 17:168-174
6. Standaert TA, Vandevanter D, Ramsey BW, et al. The choice of compressor affects the aerosol parameters and the delivery of tobramycin from a single model nebulizer. J Aerosol Med 2000; 13:47-153
7. Pitcairn GR, Newman SP. Radiolabelling of dry powder formulations. In: Dalby RN, Byron PR, Farr SJ, eds, Respiratory drug delivery VI. Buffalo Grove, IL: Interpharm Press, 1998; 397-399
8. Pitcairn GR, Lankinen T, Seppälä O-P, et al. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient's inspiratory effort. J Aerosol Med 2000; 13:97-104
9. Multistage liquid impinger. Rockville, MD: US Pharmacopeia, 1993; 19:5463
10. Pitcairn GR, Newman SP. Tissue attenuation corrections in gamma scintigraphy. J Aerosol Med 1997; 3:187-198
11. Newman SP, Clark AR, Talalee N, et al. Pressurised aerosol deposition in the human lung with and without an "open" spacer. Thorax 1989; 44:706-710
12. Newman SP, Hirst PH, Pitcairn GR, et al. Understanding regional deposition in gamma scintigraphy. In: Dalby RN, Byron PR, Farr SJ, eds. Respiratory drug delivery VI. Buffalo Grove, IL: Interpharm Press, 1998; 9-15
13. Touw DJ, Jacobs FA, Brimicombe RW, et al. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1997; 41:184-187
14. Cooney GF, Lum BL, Tomaselli M, et al. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol 1994; 34:255-259
15. PathoGenesis Corporation. TOBI: tobramycin solution for inhalation. Technical Monograph. Skokie, IL: PathoGenesis Corporation, 1999
16. O'Riordan TG, Amram JC. Effect of nebulizer configuration on delivery of aerosolized tobramycin. J Aerosol Med 1997; 10:13-23